Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Sign Up to like & getrecommendations! Published in 2019 at "Acta medica Okayama"
DOI: 10.18926/amo/57722
Abstract: Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating… read more here.
Keywords: alternating bortezomib; multiple myeloma; myeloma patients; bortezomib dexamethasone ... See more keywords
Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
Sign Up to like & getrecommendations! Published in 2022 at "Nagoya Journal of Medical Science"
DOI: 10.18999/nagjms.84.1.80
Abstract: ABSTRACT More than 40% of Japanese patients with multiple myeloma (MM) are over 75 years of age at diagnosis. Regardless of the treatment benefits, complications and relapses obstruct long-term survival. We conducted a phase II,… read more here.
Keywords: alternating bortezomib; multiple myeloma; dexamethasone lenalidomide; bortezomib dexamethasone ... See more keywords